Biomea Fusion (BMEA)
(Delayed Data from NSDQ)
$4.96 USD
+0.21 (4.42%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $4.96 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BMEA 4.96 +0.21(4.42%)
Will BMEA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BMEA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMEA
Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why
Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up
BMEA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year?
Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
Other News for BMEA
Largest borrow rate increases among liquid names
Biomea Fusion initiated with neutral view at Rodman & Renshaw
Buy Rating Affirmed for Biomea Fusion Amid Temporary Clinical Hold and Positive Outlook
Biomea Fusion Hold Recommendation Amid Clinical Setbacks and Rising Competition
Largest borrow rate increases among liquid names